BPC-157 Dosaging Guide
Research Disclaimer Content on this page is for research and educational purposes only. BioLabDirect products are sold as research chemicals and are not for human or veterinary use, diagnosis, treatment, or disease prevention. Nothing here is medical advice, a dosing protocol, or a clinical claim. Always follow institutional lab policies and applicable regulations. Tagline: For Research Purposes Only.
BPC-157 Peptide Research Guide: Structure, Mechanisms & Literature Themes
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein sequence associated with human gastric juice. Preclinical literature discusses activity across multiple tissue systems, with recurring mechanistic themes around angiogenesis (including VEGFR2-related signaling) and nitric oxide (NO) pathway modulation. This guide summarizes chemistry identifiers, literature themes, quality/storage practice, and reconstitution math as a lab technique—without clinical regimens, injection instructions, or disease-treatment claims.
Internal resources:
- Peptide reconstitution calculator
- How to order
- Related product (placeholder):
[BPC-157 research vial — link when live] - Related guide (placeholder):
GHK-Cu Complete Guide
Why BPC-157 Is Structurally Notable in Research Discussions
Unlike many designed receptor-ligand peptides, BPC-157 is discussed as a fragment related to a naturally occurring gastric protective protein. That origin is frequently linked in reviews to unusual stability in harsh biological environments relative to many linear peptides—though researchers should still validate stability under their own assay conditions.
| Identifier | Value commonly cited |
|---|---|
| Common names | BPC-157, Body Protection Compound-157, gastric pentadecapeptide BPC 157 |
| Sequence (15 aa) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Approximate MW | ~1,419.5 Da |
| CAS (commonly listed) | 137525-51-0 |
| Solubility theme in labs | Often described as freely water-soluble (confirm per lot / CoA) |
| Typical research form | Lyophilized powder for laboratory reconstitution |
Water solubility, when confirmed for a given lot, simplifies aqueous reconstitution compared with peptides that require specialized solvents. That is a handling convenience, not evidence of any approved medical use.
Dual-Pathway Themes in the Mechanistic Literature
Popular research summaries often highlight two non-exclusive mechanistic clusters. Treat these as published experimental themes, not a complete mechanism of action.
VEGFR2-linked angiogenesis
Hsieh et al. (2017) reported that BPC-157’s pro-angiogenic effects in model systems were associated with VEGFR2 expression/internalization and activation of VEGFR2–Akt–eNOS signaling, with supportive data from CAM assays, endothelial tube formation, and a rat hind-limb vascular model (PubMed 27847966; DOI 10.1007/s00109-016-1488-y).
Nitric oxide system modulation
Independent lines of work discuss interactions with NO signaling—a pathway involved in vascular tone and repair-related cellular responses. Narrative reviews sometimes describe bidirectional or context-dependent NO effects; researchers should cite primary papers for their specific model rather than over-generalizing.
Additional pathway notes in connective-tissue models
Musculoskeletal-oriented reviews mention fibroblast migration–related signaling (e.g., FAK–paxillin themes) and growth-hormone receptor expression changes in certain fibroblast/satellite-cell contexts (see Gwyer et al., 2019, for a soft-tissue literature overview). These are secondary mechanistic hypotheses layered on the angiogenesis/NO discussion—not substitutes for reading methods and effect sizes.
Tissue Systems Appearing in Preclinical Literature
No marketing claim of pan-tissue “healing” is intended. The table below maps where preclinical papers and reviews commonly report endpoints. These are model themes only, not clinical indications.
| Tissue / system theme | Example research focus in literature | Mechanistic themes often invoked |
|---|---|---|
| Tendon & ligament | Fibroblast outgrowth, tensile endpoints | Angiogenesis; FAK–paxillin–type signaling |
| Gastrointestinal models | Barrier / injury models; NSAID-related injury contexts | NO modulation; barrier integrity themes |
| Skin / wound models | Closure and strength endpoints | VEGFR2 / angiogenic support |
| Skeletal muscle tissue models | Satellite-cell / recovery endpoints | Angiogenesis; receptor-expression themes |
| Bone remodeling models | Remodeling markers in animals | Vascularization; matrix synthesis |
| Peripheral nerve models | Regeneration / neural markers | NO / vascular support themes |
| Corneal tissue models | Epithelial repair endpoints | Angiogenesis / epithelial signals |
| CNS-related models | Neurochemical / injury model endpoints | Discussed in brain–gut axis reviews |
| Cardiovascular model systems | Vascular-function models / endothelial endpoints | NO; VEGFR2-linked angiogenesis |
Gwyer et al. (2019) provide a focused review of musculoskeletal soft-tissue contexts (PubMed 30915550; DOI 10.1007/s00441-019-03016-8). Cross-tissue breadth in animal literature is a reason the compound remains of research interest; it is not regulatory approval for any indication.
Human-Study Mentions: Read Carefully
Some educational guides mention limited human investigational history in older pharmacology literature. That history is not equivalent to FDA approval, proven clinical effectiveness, or permission to use research chemicals in people.
For marketing and compliance:
- Do not describe BPC-157 as a treatment, cure, or therapy.
- Do not imply that BioLabDirect material is pharmaceutical-grade for clinical administration.
- Frame any human-study mentions as historical / investigational context in the literature, with citations, and stress that research chemicals remain not for human use.
CFO / medical-legal review should scrub any sentence that could be read as an implied clinical indication; keep model references framed as research contexts.
Preclinical Safety Literature (High Level)
Xu et al. (2020) reported a multi-species preclinical safety evaluation in Regulatory Toxicology and Pharmacology, describing study-specific findings under the conditions tested, including genetic and embryo-fetal toxicity assessments as reported by the authors (PubMed 32334036; DOI 10.1016/j.yrtph.2020.104665).
Compliance framing: Preclinical toxicology is limited to the study conditions and supports risk assessment for further research. It does not establish human safety, consumer safety, dosing guidance, or authorization for human self-administration.
BPC-157 vs Other Repair-Oriented Research Peptides
Researchers often compare tool compounds to clarify experimental design—not to recommend stacks for personal use.
| Feature | BPC-157 (literature themes) | TB-500 / Tβ4 themes | GHK-Cu themes |
|---|---|---|---|
| Size / class | 15-aa synthetic peptide | Actin-related peptide themes | Tripeptide–Cu complex |
| Frequently cited mechanisms | VEGFR2 angiogenesis; NO modulation | Actin / cell-migration themes | Copper–ECM remodeling; gene expression |
| Oral exposure in animals | Discussed for some models (verify per paper) | Typically not the same gastric-stability narrative | Different delivery literature |
| Common research niches | Soft tissue, GI models, vascular endpoints | Migration / remodeling designs | Dermal / wound / follicle models |
Related guide: GHK-Cu Complete Guide. Combination experiments require independent validation; complementary mechanisms in narrative reviews do not prove synergy.
Working With BPC-157 in Laboratory Settings
Reconstitution math (lab technique only)
BPC-157 is typically supplied lyophilized. Labs calculate concentration from mass ÷ diluent volume, then aliquot for assays. Point readers to BioLabDirect’s calculator rather than publishing clinical draw schedules:
→ Peptide reconstitution calculator
Use the calculator to convert vial mass and diluent volume into concentration and Desired aliquot volume for laboratory work. Outputs are not medical doses. Ordering workflow: How to order.
Purity and CoA expectations
Published work commonly uses high-purity synthetic peptide characterized by HPLC (often targeting ≥99% where available) and mass spectrometry confirmation of molecular weight. For cell assays, endotoxin documentation reduces confounding inflammatory artifacts.
Storage themes
| Form | Common lab practice themes |
|---|---|
| Lyophilized, sealed | Cold storage per CoA (often frozen); protect from moisture and light |
| Reconstituted | Refrigerated working solutions; avoid repeated freeze–thaw; aliquot when practical |
| Documentation | Record lot number, CoA ID, reconstitution date, diluent lot |
Exact temperatures and beyond-use dating must follow your supplier CoA and institutional SOP, not blog generalizations.
Quality Checklist When Sourcing Research Material
- Third-party or well-documented HPLC purity
- Mass spectrometry confirmation near expected MW (~1419.5 Da)
- Clear sequence / CAS labeling
- Endotoxin data for cell-based work
- Intact cold-chain and sealed lyophilized presentation
- Transparent CoA matching the shipped lot
BioLabDirect positioning for this page: educational research supply with CoA-backed lots (insert live product URL when published).
Frequently Asked Questions
Is BPC-157 the same as “Body Protection Compound 157”?
Yes—those names refer to the same pentadecapeptide commonly associated with CAS 137525-51-0. Confirm identity on the CoA for every lot.
Is BPC-157 FDA-approved?
No. It is discussed here strictly as a research chemical / research peptide. Do not use research materials as drugs.
Can BPC-157 be studied with GHK-Cu or TB-500 in the same protocol?
Some labs design multi-peptide experiments because mechanistic themes differ. That is an experimental-design choice requiring controls—not a recommended consumer “stack.” See also the GHK-Cu guide.
What does the Xu et al. 2020 paper establish?
It reports preclinical toxicology findings under defined conditions. It does not approve human use or establish a clinical dose.
How should I calculate reconstitution volumes?
Use the peptide reconstitution calculator with your vial mass and diluent volume. This is laboratory arithmetic only.
Where should I start in PubMed?
Hsieh et al., 2017 (VEGFR2/angiogenesis); Gwyer et al., 2019 (musculoskeletal review); Xu et al., 2020 (preclinical safety). Expand with model-specific primary studies for your endpoint.
Key Takeaways for Researchers
- BPC-157 is a gastric-derived sequence motif studied as a synthetic pentadecapeptide with notable preclinical breadth.
- Mechanistic literature frequently emphasizes VEGFR2-linked angiogenesis and NO modulation, with additional connective-tissue signaling notes.
- Human investigational mentions are not clinical endorsements; BioLabDirect materials remain research-only.
- Reproducibility depends on CoA purity, mass-spectrometry identity, storage discipline, and clear concentration math via the calculator.
- Tagline: For Research Purposes Only.
Selected public sources (verify on PubMed / publisher pages)
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. PMID: 27847966. DOI: 10.1007/s00109-016-1488-y.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PMID: 30915550. DOI: 10.1007/s00441-019-03016-8.
- Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID: 32334036. DOI: 10.1016/j.yrtph.2020.104665.
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. (Review context for CNS/gut themes—verify full text before citing specific claims.) PMID search via PubMed title.
Citation gaps: Specific human-study details circulating in trade blogs are unevenly documented in easily verified PubMed primary reports; do not invent trial IDs or outcomes. Prefer citing Xu (safety) and Hsieh/Gwyer (mechanism/soft tissue) unless medical-legal provides approved primary citations for human investigational history.
Research Disclaimer This article is educational only. BioLabDirect sells research chemicals not intended for human consumption or clinical use. No statements here establish safety or effectiveness for any disease or condition. Follow institutional biosafety rules. For Research Purposes Only.
